Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short Course PEG-IFN/Ribavirin in HCV Genotype 4
NCT01606800Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2013
- Primary completion
- Jan 2015
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
01
Overview
A Phase 4 trial of peginterferon alfa-2b, ribavirin in hepatitis C (HCV), sponsored by Merck & Co.. Started Jan 2013; status: terminated.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01606800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01606800.